What are the dosing, contraindications, baseline laboratory requirements, monitoring schedule, and safety considerations for tofacitinib (Xeljanz) in rheumatoid arthritis, ulcerative colitis, and psoriatic arthritis?

Tofacitinib (Xeljanz) Clinical Guide

Dosing by Indication

For rheumatoid arthritis (RA) and psoriatic arthritis (PsA), use tofacitinib 5 mg twice daily or 11 mg extended-release once daily; for ulcerative colitis (UC), use 10 mg twice daily for induction (8-16 weeks) followed by 5 mg twice daily for maintenance. 1, 2

Disease-Specific Dosing:

• RA/PsA: 5 mg twice daily (immediate-release) or 11 mg once daily (extended-release) 1
• UC Induction: 10 mg twice daily for 8 weeks (extend to 16 weeks if inadequate benefit) 1
• UC Maintenance: 5 mg twice daily (consider 10 mg twice daily in TNF-inhibitor failures) 1, 3

Dose Adjustments Required:

Renal Impairment:

• CrCl <30 mL/min: Reduce to 5 mg once daily 1
• CrCl 30-60 mL/min: No adjustment needed for tofacitinib 1

Hepatic Impairment:

• Child-Pugh C (severe): Contraindicated 1
• Moderate impairment: Use with caution

Drug Interactions:

• Rifampicin: Increases tofacitinib metabolism; consider dose increase 1
• Ketoconazole/strong CYP3A4 inhibitors: Reduce tofacitinib dose 1

Absolute Contraindications

Do not use tofacitinib in patients with active severe infections, Child-Pugh C hepatic disease, or in patients ≥65 years with cardiovascular risk factors unless no alternative exists. 1

1. Active severe infections (bacterial, viral, fungal, or opportunistic) including untreated latent tuberculosis 1
2. Severe hepatic impairment (Child-Pugh C) 1
3. Pregnancy and lactation (teratogenic in animal studies) 1

Baseline Laboratory Requirements

Before initiating tofacitinib, obtain: complete blood count, comprehensive metabolic panel, lipid panel, tuberculosis screening (IGRA or PPD), hepatitis B and C serologies, and pregnancy test in women of childbearing potential. 1

Pre-Treatment Screening:

• Complete blood count (CBC) with differential
• Comprehensive metabolic panel (hepatic and renal function)
• Lipid panel (baseline cholesterol)
• Tuberculosis screening: Interferon-gamma release assay (IGRA) or tuberculin skin test 1
• Hepatitis B surface antigen and core antibody
• Hepatitis C antibody
• Pregnancy test (women of childbearing potential)

Vaccination Requirements:

Complete all age-appropriate vaccinations, including herpes zoster vaccine, at least 2-4 weeks before starting tofacitinib. 2 Live vaccines are contraindicated once therapy begins 2.

Monitoring Schedule

Monitor CBC, liver enzymes, and lipids at 4-8 weeks after initiation, then every 3 months thereafter; interrupt therapy if ANC <1000/mm³, ALC <500/mm³, or hemoglobin <8 g/dL. 1

Laboratory Monitoring Timeline:

Weeks 4-8 after initiation:

• CBC with differential
• Hepatic transaminases (ALT/AST)
• Lipid panel

Every 3 months ongoing:

• CBC with differential
• Hepatic function tests
• Lipid panel (if abnormal at baseline)

Thresholds for Dose Interruption:

• Absolute neutrophil count (ANC) <1000/mm³: Hold therapy 1
• Absolute lymphocyte count (ALC) <500/mm³: Hold therapy 1
• Hemoglobin <8 g/dL: Hold therapy 1
• ALT/AST >3× upper limit of normal: Hold therapy 1

Critical Safety Considerations

Age and Cardiovascular Risk

In patients ≥65 years with cardiovascular risk factors, tofacitinib carries increased risks of serious infections, major adverse cardiovascular events (MACE), and thrombosis compared to TNF inhibitors; use only if no alternative exists. 1 The 10 mg twice daily dose is particularly problematic in elderly patients, showing several-fold higher serious infection rates 1.

Infection Risk

Herpes zoster is the most common serious infection (IR 1.8-3.6 per 100 patient-years), followed by serious bacterial infections (IR 1.2-2.5 per 100 patient-years). 4 Risk is dose-dependent and higher in UC patients 4, 5.

Thrombosis Risk

Venous thromboembolism (VTE) and pulmonary embolism (PE) risks are elevated, particularly with the 10 mg twice daily dose. 2 Avoid in patients with prior thrombotic events or high VTE risk factors.

Malignancy

While no clear malignancy signal exists in registries, most trials excluded patients with malignancy within 5 years; use shared decision-making for patients with prior malignancy. 1

Gastrointestinal Perforation

Monitor for new-onset abdominal symptoms, particularly in patients with diverticular disease or concurrent NSAID/corticosteroid use 2.

Special Populations

Ulcerative Colitis Dose Optimization

For UC patients achieving clinical response at 8 weeks on 10 mg twice daily, reduce to 5 mg twice daily for maintenance; use endoscopic subscore to guide dose reduction decisions. 3 If relapse occurs on 5 mg twice daily, response can be recaptured in most patients by increasing back to 10 mg twice daily 3.

Psoriatic Arthritis with Methotrexate

Patients stable on tofacitinib 5 mg twice daily plus methotrexate for ≥3 months can discontinue methotrexate without clinically meaningful worsening of disease activity. 6 However, liver enzyme elevations are more common with combination therapy 6.

Common Pitfalls to Avoid

1. Using 10 mg twice daily long-term in RA/PsA: This dose is not recommended due to increased cardiovascular and thrombotic risks 1, 2

2. Inadequate tuberculosis screening: Always screen and treat latent TB before initiation; remember rifampicin increases tofacitinib metabolism requiring dose adjustment 1

3. Ignoring age-related risks: Patients ≥65 years have substantially higher serious infection rates, particularly at higher doses 1

4. Premature dose reduction in UC: Wait until week 8 to assess response before reducing from induction to maintenance dosing 3

5. Overlooking XELJANZ XR formulation risks: The extended-release formulation is non-deformable and contraindicated in patients with severe GI narrowing 2